Posts

Psychedelic Business Spotlight – December 17

Psychedelic Business Spotlight – December 17

This week in psychedelic business news: Cybin steps closer to a new patent; MindMed appoints new CEO; MAPS and Wesana Health resume negotiations.

Psychedelic Business Spotlight: December 3

This week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a Cybin study for Covid-19 distress; Compass Pathways gets new majority stakeholder.
Psychedelic Business Spotlight: November 26

Psychedelic Business Spotlight: November 26

This week in psychedelic business news: Compass Pathways files another patent; Seelos Therapeutics raises big money; Cybin makes psychedelic therapy more accessible in NYC.
PharmaTher Believes Ketamine Could Treat This Rare Neurological ConditionShutterstock.com

PharmaTher Believes Ketamine Could Treat This Rare Neurological Condition

,
The company is also exploring if ketamine can treat other neurological conditions, including Parkinson’s Disease, ALS, and CRPS.

Psychedelic Business Spotlight: November 12

This week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps MAPS expand MDMA study; and Ketamine One announces IPO intention.
Psychedelic Business Spotlight: November 5

Psychedelic Business Spotlight: November 5

This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.

Psychedelic Business Spotlight: October 15

This week in psychedelic business news: Cybin inhales; atai Life Sciences expands; DEA grants new psilocybin license; and FDA backs ketamine.
FDA Backs Ketamine for Rare Pain Disorder with No Current Medical Treatment

FDA Backs Ketamine to Treat This Rare and Debilitating Pain Syndrome

Food and Drug Administration grants psychedelic biotechnology company PharmaTher orphan drug designation for ketamine to treat complex regional pain syndrome.
Psychedelic Business Spotlight: October 8, 2021

Psychedelic Business Spotlight: October 8, 2021

This week in psychedelic business news: Enveric Biosciences uses AI to identify viable psychedelic drug candidates; Novamind launches end-of-life palliative care program; and PharmaTher tests ketamine to treat Parkinson's Disease.
FDA Green Lights Ketamine for Treatment of ALS

FDA Green Lights Ketamine for Treatment of ALS

,
"This designation not only expedites our regulatory, clinical, and product development plans but also validates our belief in the potential of ketamine," says PharmaTher CEO Fabio Chianelli.